François defended his PhD in 1991, at the Pasteur Institute in Paris, in the lab of François Jacob. Then, he did his Post-doc at Genentech in the US. After that, he joined the GSK Research Institute of Geneva where he worked as a scientist in CNS research until 2001. His main field of interest was to validate metabotropic Glutamate receptors for CNS diseases. Then, he left GSK to found Addex Pharmaceuticals in Geneva, where he stayed CEO until 2005. Addex is a Biotech company dedicated to the discovery of novel treatments for CNS diseases and particularly focused on the development of mGluR5 antagonists. In 2005, he worked as an acting CEO for a VC firm in three different French Biotechs, before joining Merck Serono in September 2006 as Director, Early Stage Licensing, where he managed the in-licensing of several novel preclinical programs. François is the author of more than 40 peer reviewed scientific articles and inventor in 2 patents.
Delphine defended her PhD in Neurosciences in 2005 in Paris. Then she pursued postdoctoral studies at EPFL for two years, in the laboratory of Pr Patrick Aebischer. In 2008, Delphine joined Addex Pharmaceuticals as Laboratory Head in in vitro pharmacology, being responsible for all the in vitro pharmacology experiments needed to characterize allosteric modulators (PAM, NAM and SAM) of mGluRs and other GPCR. Delphine was named Biology Project Leader for two of the main CNS drug discovery projects of Addex, including the development of mGluR4 PAMs for the treatment of Parkinson’s disease, a project partnered with Merck & Co. In 2010, Delphine joined Merck-Serono as Senior Scientist and Project Leader, managing the Geneva Parkinson’s disease in vitro laboratory. She was actively involved in drug discovery projects. She also proposed and initiated a project to discover and develop mGluR3 PAMs as a treatment of Parkinson’s disease and other neurodegenerative disorders.
Dr. Medori is our chief medical officer. Dr. Medori brings to Prexton more than 20 years of neuroscience expertise and an extensive track record in CNS drug development with contributions in neurological areas, including multiple sclerosis, Parkinson’s and Alzheimer’s disease, and in psychiatry with important work in Depression, Schizophrenia and Attention Deficit Hyperactivity Disorders (ADHD). Preceding his appointment at Prexton, Dr. Medori spent 6 years at Biogen, during which time she held several key leadership roles, including VicePresident of Translational Neurology and Vice President of Clinical Development. As VicePresident of Biogen, she was responsible for establishing the translational neurology strategy and organization and contributed to the registration of key drugs for the treatment of multiple sclerosis. Prior to Biogen, Dr. Medori served as European and Global Medical at Janssen Cilag, as Neuroscience Medical Director and European Brand Leader at BMS and as Medical director and member of the company neurology strategy board at Lilly. She has practiced as a Clinical Neurologist in Italy, the United States and Germany and held various academic positions at Case Western Reserve University, Cleveland (OH), Washington University in St. Louis and Columbia University in New York (NY). For several years, she has lectured on Neurology at Philipps University in Marburg, Germany and was invited to be Visiting Professor of Neuropsychopharmacology at the San Raffaele Institute of the Universita' Cattolica in Milan. The identification of the DNA mutations associated to with different forms of muscular dystrophy and the description of a new prion disease which is part of a group of lethal diseases, including BSE and Mad Cow disease) called Fatal Familial Insomnia are among her most important scientific contributions.
Dr. Medori holds a M.D. from the University of Bologna, School of Medicine, Italy and is certified to practice medicine in Italy, USA and Germany. She carried out her residency in Neurology at the Neurological Hospital of the University of Bologna (Italy) and at Case Western Reserve University in Cleveland (OH).
Nicolas brings Prexton more than 15 years of executive experience in healthcare and industrial finance, with earlier career tenure in engineering. Prior to Prexton Therapeutics, he was CFO of Endosense, a MedTech start-up company acquired by St Jude Medical for CHF 309M in 2013. Previously, he held various managerial positions within Merck Serono’s commercial controlling, forecasting and internal audit departments, where he developed an expertise in business development in the pharmaceutical industry. During his time at Merck Serono, he, among other achievements, negotiated in licensing deals with big pharmaceutical partners. Earlier in his career, Nicolas held the position of manager of internal auditing at Saint Gobain, the world leader in the habitat and construction markets, and was also a research engineer at Péchiney (currently ALCAN), a major aluminum conglomerate. Nicolas holds an Engineering degree from Ecole des Mines de Paris, France, and a Master degree in Mechanical Engineering form Northwestern University, Chicago, USA. He is also the founder of Bees4You, a start-up company in the field of sustainable development.
Duc Tran has nineteen year experience in drug discovery and drug development, working for large pharmaceutical companies (Sanofi-Aventis, Pfizer) and start-ups (Preglem, Arisgen, EspeRare) and has extensive experience working across a range of target classes in multiple disease areas encompassing cardiovascular, anti-infective, urology, epigenetics, CNS and reproductive medicine, delivering a large number of projects into clinical development, up to PhIIa Proof of Concept. Duc is responsible for providing IND-enabling Preclinical, Early Clinical, and Chemistry, Manufacturing and Control (CMC) leadership for the drug development programs to support regulatory submission.
Duc graduated from the French Grandes Ecoles d’ingénieurs ESPCI in Physics, Chemistry and Biology. He also holds a MSc degree in organic and bioorganic chemistry and is a registered Project Manager. Duc has published twenty articles in peer reviewed journals and is a named inventor on seven patents.